If Analyst Forecast Holds TrueSeres Therapeutics, Inc. (MCRB) Will Hit $13 Per Share

It has been reported that multiple insider activity took place at Seres Therapeutics, Inc. (MCRB). The insider Shaff Eric D. sold 4,378 shares for $12,842 in transaction occurred on 2019/01/28. After making this transaction, The insider owns a direct stake of -26 shares, worth $54,322, as per the last closing price. On 2019/01/28 DesRosier Thomas, Chief Legal Officer and EVP at MCRB, dumped 5,471 shares at an average price of $5.75 per share. The selling total is valued at $67,908.

Chief Technology Officer & EVP, Aunins John G. had divested 14,282 shares for $85,250 through a trade on 2018/12/17. Following this activity, the insider holds -34 shares worth $360,608 as of recent close.

ARK ETF Tr-ARK Innovation ETF revealed as top hedge fund owner in Seres Therapeutics, Inc. (MCRB) with a stake of over 2.18M MCRB shares as of October 30, with a market value of approx. $15.01M as of today. The second largest holder, Fidelity Select Portfolios – Biotechnology, with 1.99M shares which equates to $13.67M worth of the stock. At third is Fidelity Growth Company Fund, which stood pat with 1.52M shares, a 5.76% position in Seres Therapeutics, Inc., worth $10.42M. The insider holding in stood at 0.7% while institutions hold 82.2%.

Seres Therapeutics, Inc. (NASDAQ:MCRB) dropped -0.47% in recent trade and currently has a stock-market value of $180.62M. The shares finished at $4.23, after trading as low as $4.16 earlier in the session. It hit an intraday high Wednesday at $4.39. Trading activity significantly weakened as the volume at ready counter decreased to 175,356 shares versus 210,990 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 302,361 shares. The stock is now 2.42% above against its bear-market low of $4.13 on May 14, 2019. It has retreated -130.5% since it’s 52-week high of $9.75 reached in June. Now the market price is down -48.85% on the year and down -6.42% YTD.

MCRB stock’s 50 day simple moving average (SMA 50) price is $6.23 and its 200-day simple moving average (SMA 200) price is $6.79. The company’s stock currently has a total float of 33.91M shares. Its weekly volatility is hovering around 6.56% and felt 6.83% volatility in price over a month. On the upside, the share price will test short term resistance at around $4.36. On a downside, the stock is likely to find some support, which begins at $4.13. The failure to get near-term support could push it to $4.03.

It had seen a new analyst call from Jefferies, which initiated the stock at Hold on April 30. Analysts at Chardan Capital Markets, started covering the stock on October 22 with a Buy rating. Analysts at Oppenheimer, made their first call about the stock on October 13, recommending it is Outperform. H.C. Wainwright, reiterated their call for Buy, on August 04. On the other hand, they had set new target price to $19 versus $15.

MCRB’s ROE is 235.9%, which is also considerably better than the industry’s ROE of 8.4%. It’s also very liquid in the near term, with a current ratio of 1.6. The stock has a debt/capital of 0.

Shares of MCRB have dropped -30.4% since the company’s most recent earnings report. Over the past 12 fiscal quarters, Seres Therapeutics, Inc. (NASDAQ:MCRB) has topped consensus earnings estimates in 9 quarters (75%), missed earnings in 3 quarters (25%), whereas at 0 occasion EPS met analyst expectations. MCRB last reported earnings that receded expectations. The company raked in -$0.59 per share, -98.8% change on the same period last year. That was worse than consensus for -$0.4. Revenue for the recent quarter stood at $7.32 million, up 84% on last year and below the $15.31 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $3.9 million to $11.9 million, which should be compared with $5.6 million generated last year. EPS is seen in a range of -$0.7 to -$0.4, against the -$0.63 reported a year ago.